$30.91
0.96% day before yesterday
Nasdaq, Nov 28, 07:00 pm CET
ISIN
US86150R1077
Symbol
STOK

Stoke Therapeutics Inc Stock price

$30.91
-0.72 2.28% 1M
+21.48 227.78% 6M
+19.88 180.24% YTD
+19.00 159.53% 1Y
+23.57 321.12% 3Y
-21.18 40.66% 5Y
+12.91 71.72% 10Y
+12.91 71.72% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-0.30 0.96%
ISIN
US86150R1077
Symbol
STOK
Industry

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$1.5b
Net debt
positive
Cash
$248.3m
Shares outstanding
55.1m
Valuation (TTM | estimate)
P/E
44.2 | 104.3
P/S
8.6 | 9.4
EV/Sales
7.4 | 8.0
EV/FCF
28.9
P/B
5.7
Financial Health
Equity Ratio
84.3%
Return on Equity
-38.9%
ROCE
8.4%
ROIC
27.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$205.6m | $188.8m
EBITDA
$28.7m | $13.2m
EBIT
$26.8m | $3.0m
Net Income
$41.1m | $16.3m
Free Cash Flow
$52.6m
Growth (TTM | estimate)
Revenue
1,128.4% | 416.5%
EBITDA
125.1% | 113.3%
EBIT
123.0% | 103.0%
Net Income
139.0% | 118.4%
Free Cash Flow
161.8%
Margin (TTM | estimate)
Gross
-
EBITDA
14.0% | 7.0%
EBIT
13.1%
Net
20.0% | 8.7%
Free Cash Flow
25.6%
More
EPS
$0.7
FCF per Share
$1.0
Short interest
23.6%
Employees
128
Rev per Employee
$290.0k
Show more

Is Stoke Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Stoke Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Stoke Therapeutics Inc forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Stoke Therapeutics Inc forecast:

Buy
88%
Hold
12%

Financial data from Stoke Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
206 206
1,128% 1,128%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 59 59
26% 26%
29%
- Research and Development Expense 120 120
37% 37%
58%
29 29
125% 125%
14%
- Depreciation and Amortization 1.90 1.90
16% 16%
1%
EBIT (Operating Income) EBIT 27 27
123% 123%
13%
Net Profit 41 41
139% 139%
20%

In millions USD.

Don't miss a Thing! We will send you all news about Stoke Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Stoke Therapeutics Inc Stock News

Positive
Investors Business Daily
about 23 hours ago
Biotech stocks have a strong presence on the elite IBD 50 list of growth stocks.
Neutral
Business Wire
11 days ago
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on Novemb...
Neutral
Business Wire
12 days ago
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ: BIIB) today announced the publication of final data from the BUTTERFLY study, a prospective, two-year natural history study in people with Dravet syndrome. Dr...
More Stoke Therapeutics Inc News

Company Profile

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues, including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Head office United States
CEO Ian Smith
Employees 128
Founded 2014
Website www.stoketherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today